Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib
- Resource Type
- Article
- Source
- In
Clinical Lung Cancer May 2022 23(3):e210-e221 - Subject
- Language
- ISSN
- 1525-7304